DOP2023000091A - Composiciones de inhibidores peptídicos del receptor de interleucina-23 - Google Patents
Composiciones de inhibidores peptídicos del receptor de interleucina-23Info
- Publication number
- DOP2023000091A DOP2023000091A DO2023000091A DO2023000091A DOP2023000091A DO P2023000091 A DOP2023000091 A DO P2023000091A DO 2023000091 A DO2023000091 A DO 2023000091A DO 2023000091 A DO2023000091 A DO 2023000091A DO P2023000091 A DOP2023000091 A DO P2023000091A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compositions
- interleukin
- receptor
- peptide inhibitors
- diseases
- Prior art date
Links
- 102100036672 Interleukin-23 receptor Human genes 0.000 title abstract 3
- 101710195550 Interleukin-23 receptor Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 239000012453 solvate Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Ceramic Engineering (AREA)
- Toxicology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se relaciona con composiciones de inhibidores peptídicos del receptor de interleucina-23 (IL-23R) o sal farmacéuticamente aceptable o formas de solvato de estos, composiciones farmacéuticas correspondientes, métodos y/o usos para el tratamiento de la inflamación autoinmunitaria y enfermedades y trastornos relacionados.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063116568P | 2020-11-20 | 2020-11-20 | |
US202163275222P | 2021-11-03 | 2021-11-03 | |
PCT/US2021/060183 WO2022109328A1 (en) | 2020-11-20 | 2021-11-19 | Compositions of peptide inhibitors of interleukin-23 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2023000091A true DOP2023000091A (es) | 2023-12-29 |
Family
ID=81708151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2023000091A DOP2023000091A (es) | 2020-11-20 | 2023-05-12 | Composiciones de inhibidores peptídicos del receptor de interleucina-23 |
Country Status (15)
Country | Link |
---|---|
US (1) | US11939361B2 (es) |
EP (1) | EP4247403A1 (es) |
JP (1) | JP7397239B2 (es) |
KR (1) | KR20230110570A (es) |
AU (1) | AU2021383828A1 (es) |
CA (1) | CA3202226A1 (es) |
CL (1) | CL2023001417A1 (es) |
CO (1) | CO2023007172A2 (es) |
DO (1) | DOP2023000091A (es) |
IL (1) | IL302996A (es) |
MX (1) | MX2023005994A (es) |
PE (1) | PE20240631A1 (es) |
TW (1) | TW202237167A (es) |
UY (1) | UY39527A (es) |
WO (1) | WO2022109328A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201507226YA (en) | 2013-03-15 | 2015-10-29 | Protagonist Therapeutics Inc | Hepcidin analogues and uses therof |
ES2890600T3 (es) | 2014-05-16 | 2022-01-20 | Protagonist Therapeutics Inc | Péptidos de tioéter antagonistas de integrina alfa4beta7 |
BR112017001010A2 (pt) | 2014-07-17 | 2017-11-14 | Protagonist Therapeutics Inc | inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais |
EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
CN118005736A (zh) | 2020-01-15 | 2024-05-10 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
WO2024003313A1 (en) | 2022-06-30 | 2024-01-04 | Sanofi | New peptides as selective il-23 receptor antagonists |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
US4724229A (en) | 1986-09-30 | 1988-02-09 | Smithkline Beckman Corporation | Arg-arg-arg-vasopressin antagonists |
JPH02306947A (ja) | 1989-05-01 | 1990-12-20 | Monsanto Co | キラルβ―アミノ酸の製造方法 |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
DK0578728T3 (da) | 1991-04-05 | 1999-04-12 | Genentech Inc | Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa |
US5569741A (en) | 1992-07-27 | 1996-10-29 | Biomeasure, Inc. | Cyclic octapeptide neuromedin B receptor antagonists |
WO1994011018A1 (en) | 1992-11-12 | 1994-05-26 | Biomeasure, Inc. | Opioid peptides |
AU673731B2 (en) | 1993-06-03 | 1996-11-21 | Banyu Pharmaceutical Co., Ltd. | Novel endothelin antagonistic peptide |
US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
US5990084A (en) | 1996-04-19 | 1999-11-23 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
US7122623B2 (en) | 1996-07-12 | 2006-10-17 | Adherex Technologies, Inc. | Compounds and methods for modulating cell adhesion |
HU227021B1 (en) | 1996-08-30 | 2010-05-28 | Novo Nordisk As | Glp-1 derivatives |
US5942492A (en) | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
US5993811A (en) | 1997-02-03 | 1999-11-30 | Biology Associates, Llc | Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis |
JP2001509493A (ja) | 1997-07-11 | 2001-07-24 | インナーダイン, インコーポレイテッド | 放射送達構造体の調製およびシール化のための方法およびシステム |
US6818617B1 (en) | 1997-08-15 | 2004-11-16 | Temple University- Of The Commonwealth System Of Higher Education | EC-3, an inhibitor of α4β1 and α4β7 integrins |
AU750175B2 (en) | 1997-11-24 | 2002-07-11 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
US8038984B2 (en) | 1998-06-20 | 2011-10-18 | Washington University | Membrane-permeant peptide complexes for treatment of sepsis |
JP2002524108A (ja) | 1998-07-28 | 2002-08-06 | インナーダイン, インコーポレイテッド | 吸収性近接照射療法および化学療法送達デバイスならびに方法 |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
AUPP616498A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Synthesis of cyclic peptides |
AUPP616598A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Auxiliary for amide bond formation |
AUPP660698A0 (en) | 1998-10-21 | 1998-11-12 | University Of Queensland, The | A method of protein engineering |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
WO2000055119A1 (en) | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
KR20010110750A (ko) | 1999-04-12 | 2001-12-13 | 앤드류 앵뉴 | 인테그린 길항제로서의 치환된 비사이클릭 헤테로아릴화합물 |
WO2001068586A2 (en) | 2000-03-14 | 2001-09-20 | Novartis Ag | α4β1 AND α4β7 INTEGRIN INHIBITORS |
US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
WO2002055106A2 (en) | 2001-01-09 | 2002-07-18 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
DE10107707A1 (de) | 2001-02-19 | 2002-08-29 | Wilex Biotechnology Gmbh | Antagonisten für alpha¶4¶beta¶7¶-Integrin |
AUPS039702A0 (en) | 2002-02-08 | 2002-03-07 | University Of Queensland, The | Common protein surface shapes and uses therefor |
US20030166138A1 (en) | 2002-02-21 | 2003-09-04 | Todd Kinsella | Cyclic peptides and analogs useful to treat allergies |
EP1523557A2 (en) | 2002-07-24 | 2005-04-20 | Intercell AG | Antigens encoded by alternative reading frame from pathogenic viruses |
WO2004058307A1 (en) | 2002-12-18 | 2004-07-15 | Wyeth | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
AU2004231122B2 (en) | 2003-04-15 | 2010-04-08 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof |
CA2544223C (en) | 2003-11-05 | 2017-03-07 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
US20060030053A1 (en) | 2003-12-19 | 2006-02-09 | Applera Corporation | Methods and systems for protein and peptide evidence assembly |
BR122021007893B1 (pt) | 2004-01-09 | 2022-04-12 | Pfizer Inc. | Anticorpo monoclonal, ou fração de ligação a antígeno do mesmo que se liga especificamente a madcam, composição farmacêutica, vacina e kit de diagnostico |
US8536140B2 (en) | 2004-03-12 | 2013-09-17 | Mti Meta Tech Inc. | Methods for treating inflammatory bowel disease |
WO2006000034A1 (en) | 2004-06-24 | 2006-01-05 | The Walter And Eliza Hall Institute Of Medical Research | Conjugates and therapeutic uses thereof |
NZ554331A (en) | 2004-09-23 | 2009-04-30 | Univ Melbourne | Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection |
WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
JP2008521840A (ja) | 2004-11-30 | 2008-06-26 | ガストロテック・ファルマ・アクティーゼルスカブ | 成長ホルモン分泌促進物質レセプター1aリガンド |
US20100183617A1 (en) | 2005-02-23 | 2010-07-22 | University Of Virginia Patent Foundation | Compositions and methods for regulating sas1r |
US7534764B2 (en) | 2005-06-29 | 2009-05-19 | The Regents Of The University Of California | Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin |
CA2622441A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
EP2016177A2 (en) | 2006-04-12 | 2009-01-21 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
WO2007134395A1 (en) | 2006-05-22 | 2007-11-29 | Clinical Genomics Pty Ltd | Detection method |
GB0610395D0 (en) | 2006-05-25 | 2006-07-05 | Ge Healthcare Ltd | Novel imaging agents |
CA2655372A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
US20080019913A1 (en) | 2006-07-07 | 2008-01-24 | University Of Arizona Office Of Technology Transfer | Enkepahlin analogs with improved bioavailability |
KR101399175B1 (ko) | 2006-07-21 | 2014-06-19 | 푼다싸웅 지 앙빠루 아 뻬스끼자 두 에스따두 지 싸웅 파울루 - 에피아뻬에에씨뻬 | 항염증성 및 항알레르기성 시클릭 펩티드 |
WO2008045252A2 (en) | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
EP2109480B1 (en) | 2006-12-07 | 2017-06-28 | The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services | Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin |
WO2008097461A2 (en) | 2007-02-02 | 2008-08-14 | Amgen Inc | Hepcidin and hepcidin antibodies |
NZ578948A (en) | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
JP2010518856A (ja) | 2007-02-23 | 2010-06-03 | シェーリング コーポレイション | 操作された抗−IL−23p19抗体 |
US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
EP2150564A2 (en) | 2007-04-27 | 2010-02-10 | ZymoGenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
WO2008144041A1 (en) | 2007-05-21 | 2008-11-27 | The Ohio State University Research Foundation | Hepcidins as biomarkers for impending lupus nephritis flare |
US20090131317A1 (en) | 2007-06-22 | 2009-05-21 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
EP2288621A4 (en) | 2007-07-06 | 2012-01-04 | Valorisation Hsj Soc En Commandite | IL23 RECEPTOR ANTAGONISTS AND THEIR USE |
CN101358201A (zh) | 2007-07-31 | 2009-02-04 | 钱忠明 | 重组人铁调素腺病毒、其制备方法及应用 |
CN101307085B (zh) | 2007-08-01 | 2012-06-13 | 香港理工大学深圳研究院 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
GR1006896B (el) | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
WO2009039185A1 (en) | 2007-09-17 | 2009-03-26 | The Trustees Of Columbia University In The City Of New York | Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation |
US20100280098A1 (en) | 2007-10-05 | 2010-11-04 | Juliano Rudolph L | Receptor targeted oligonucleotides |
EP2352762A1 (en) | 2008-11-03 | 2011-08-10 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
EP3208279B1 (en) | 2008-12-05 | 2021-04-21 | The Regents of The University of California | Mini-hepcidin peptides and methods of using thereof |
DE102009007381A1 (de) | 2009-01-29 | 2010-08-05 | Amp-Therapeutics Gmbh & Co. Kg | Antibiotische Peptide |
US8999935B2 (en) | 2009-02-11 | 2015-04-07 | New York University | Treatment of osteoporosis in peri- and post-menopausal women with hepcidin |
WO2010116752A1 (ja) | 2009-04-08 | 2010-10-14 | 武田薬品工業株式会社 | ニューロメジンu誘導体 |
TWI578992B (zh) | 2009-04-30 | 2017-04-21 | 諾克森製藥股份有限公司 | 與鐵調節激素(hepcidin)結合之核酸類 |
US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
US20120329730A1 (en) | 2010-01-25 | 2012-12-27 | Institut De Recherches Cliniques De Montreal | Aromatic-cationic peptides and uses of same |
US10416172B2 (en) | 2010-03-31 | 2019-09-17 | Medical Diagnostic Laboratories, Llc | Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling |
JP2011231085A (ja) | 2010-04-30 | 2011-11-17 | Osaka Prefecture Univ | 環状ペプチド |
WO2011149942A2 (en) | 2010-05-24 | 2011-12-01 | Children's Medical Center Corporation | Compositions and methods for plasma peptide analysis |
IT1406051B1 (it) | 2010-08-05 | 2014-02-06 | D M G Italia S R L | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. |
ES2919136T3 (es) | 2010-08-11 | 2022-07-22 | Ironwood Pharmaceuticals Inc | Formulaciones estables de linaclotida |
EP2444101A1 (en) | 2010-10-21 | 2012-04-25 | Universitätsklinikum Freiburg | Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis |
US9243034B2 (en) | 2011-01-27 | 2016-01-26 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
US9169292B2 (en) | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
AU2012271691A1 (en) | 2011-06-14 | 2014-01-16 | Stealth Peptides International, Inc. | Aromatic-cationic peptides and uses of same |
US9605027B2 (en) | 2011-06-14 | 2017-03-28 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
CN104011066A (zh) | 2011-12-09 | 2014-08-27 | 加利福尼亚大学董事会 | 经修饰的微型铁调素肽及其使用方法 |
US20150157692A1 (en) | 2012-05-23 | 2015-06-11 | The University Of Chicago | Methods of treating obesity |
US9024044B2 (en) | 2012-06-14 | 2015-05-05 | Ajinomoto Co., Inc. | Heteroarylcarboxylic acid ester derivative |
US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
AU2014216091A1 (en) | 2013-02-15 | 2015-09-03 | Srx Cardio, Llc | Proprotein convertase subtilisin/kexin type 9 allosteric binding ligands to modulate serum low density lipoprotein |
SG11201507226YA (en) | 2013-03-15 | 2015-10-29 | Protagonist Therapeutics Inc | Hepcidin analogues and uses therof |
US20140294902A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide antagonists |
US20140294901A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide dimer antagonists |
EP3013351B1 (en) | 2013-06-24 | 2019-10-30 | CanBas Co., Ltd. | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations |
CA2916492A1 (en) | 2013-06-27 | 2014-12-31 | Stealth Biotherapeutics Corp | Peptide therapeutics and methods for using same |
EP3065757A4 (en) | 2013-10-09 | 2017-08-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
WO2015112700A1 (en) | 2014-01-22 | 2015-07-30 | Wisconsin Alumni Research Foundation | Alpha/beta-peptide mimics of z-domain peptides |
EP3129040A4 (en) | 2014-04-07 | 2018-03-21 | La Jolla Pharmaceutical Company | Hepdicin mimetic peptides and uses thereof |
ES2890600T3 (es) | 2014-05-16 | 2022-01-20 | Protagonist Therapeutics Inc | Péptidos de tioéter antagonistas de integrina alfa4beta7 |
WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
AU2015279571A1 (en) | 2014-06-27 | 2017-02-02 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses therof |
WO2016004093A2 (en) | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
BR112017001010A2 (pt) | 2014-07-17 | 2017-11-14 | Protagonist Therapeutics Inc | inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais |
SG11201702553RA (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics Inc | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
WO2016054445A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
WO2016109363A1 (en) | 2014-12-29 | 2016-07-07 | The Regents Of The University Of California | S-Alkylated Hepcidin Peptides and Methods of Making and Using Thereof |
US20160199437A1 (en) | 2015-01-08 | 2016-07-14 | D. Travis Wilson | Therapeutic compositions including iron chelators and uses thereof |
WO2016115168A1 (en) | 2015-01-12 | 2016-07-21 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
US20160228491A1 (en) | 2015-02-09 | 2016-08-11 | Stealth Biotherapeutics Corp | Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof |
WO2016195663A1 (en) | 2015-06-02 | 2016-12-08 | Stealth Peptides International, Inc. | Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof |
WO2016200364A1 (en) | 2015-06-08 | 2016-12-15 | Stealth Peptides International, Inc. | THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
SG10201912066SA (en) | 2015-07-15 | 2020-02-27 | Protagonist Therapeutics Inc | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
WO2017165676A1 (en) | 2016-03-23 | 2017-09-28 | Protagonist Therapeutics, Inc. | METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS |
US20190270786A1 (en) | 2016-07-27 | 2019-09-05 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
WO2018022917A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Disulfide-rich peptide libraries and methods of use thereof |
WO2018089693A2 (en) | 2016-11-09 | 2018-05-17 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
CA3046171A1 (en) | 2016-12-06 | 2018-06-14 | Stichting Voor De Technische Wetenschappen | Multicyclic peptides and methods for their preparation |
AU2018210174B2 (en) | 2017-01-18 | 2022-04-07 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
EP4092038A1 (en) | 2017-09-11 | 2022-11-23 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
EP3810094A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
JOP20190150A1 (ar) | 2018-06-21 | 2019-12-21 | Merck Sharp & Dohme | مركبات مناهضة لـ pcsk9 |
EP3820883A4 (en) | 2018-07-12 | 2022-04-20 | Protagonist Therapeutics, Inc. | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES |
US20220185846A1 (en) | 2019-03-28 | 2022-06-16 | Protagonist Therapeutics, Inc. | Methods for synthesizing beta-homoamino acids |
WO2021007433A1 (en) | 2019-07-10 | 2021-01-14 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
MX2022000397A (es) | 2019-07-10 | 2022-04-25 | Protagonist Therapeutics Inc | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
US20220372099A1 (en) | 2019-09-03 | 2022-11-24 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
AU2021205415A1 (en) | 2020-01-10 | 2022-07-21 | Protagonist Therapeutics, Inc. | Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists |
BR112022014011A2 (pt) | 2020-01-15 | 2022-12-20 | Janssen Biotech Inc | Inibidores peptídicos de receptor de interleucina-23 e seu uso no tratamento de doenças inflamatórias |
WO2021146458A1 (en) | 2020-01-15 | 2021-07-22 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
CN118005736A (zh) | 2020-01-15 | 2024-05-10 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
JP2023536463A (ja) | 2020-07-28 | 2023-08-25 | プロタゴニスト セラピューティクス, インコーポレイテッド | コンジュゲート型ヘプシジン模倣体 |
AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
WO2022212698A1 (en) | 2021-04-01 | 2022-10-06 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
EP4314017A1 (en) | 2021-04-01 | 2024-02-07 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
EP4314014A2 (en) | 2021-04-01 | 2024-02-07 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
KR20240021833A (ko) | 2021-06-14 | 2024-02-19 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | 유전성 혈색소 침착증의 치료를 위한 헵시딘 모방체 |
PE20240595A1 (es) | 2021-07-14 | 2024-03-21 | Janssen Biotech Inc | Inhibidores peptidicos lipidicos del receptor de iinterleucina-23 |
TW202321275A (zh) | 2021-07-14 | 2023-06-01 | 美商健生生物科技公司 | 介白素—23受體之雙環肽抑制劑 |
CA3226539A1 (en) | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor |
-
2021
- 2021-11-19 AU AU2021383828A patent/AU2021383828A1/en active Pending
- 2021-11-19 PE PE2023001697A patent/PE20240631A1/es unknown
- 2021-11-19 US US17/531,538 patent/US11939361B2/en active Active
- 2021-11-19 IL IL302996A patent/IL302996A/en unknown
- 2021-11-19 EP EP21895709.0A patent/EP4247403A1/en active Pending
- 2021-11-19 WO PCT/US2021/060183 patent/WO2022109328A1/en active Application Filing
- 2021-11-19 MX MX2023005994A patent/MX2023005994A/es unknown
- 2021-11-19 TW TW110143278A patent/TW202237167A/zh unknown
- 2021-11-19 CA CA3202226A patent/CA3202226A1/en active Pending
- 2021-11-19 JP JP2023530551A patent/JP7397239B2/ja active Active
- 2021-11-19 KR KR1020237020799A patent/KR20230110570A/ko unknown
- 2021-11-22 UY UY0001039527A patent/UY39527A/es unknown
-
2023
- 2023-05-12 DO DO2023000091A patent/DOP2023000091A/es unknown
- 2023-05-17 CL CL2023001417A patent/CL2023001417A1/es unknown
- 2023-05-31 CO CONC2023/0007172A patent/CO2023007172A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20240631A1 (es) | 2024-03-26 |
CL2023001417A1 (es) | 2023-12-15 |
WO2022109328A1 (en) | 2022-05-27 |
AU2021383828A1 (en) | 2023-07-06 |
UY39527A (es) | 2022-06-30 |
KR20230110570A (ko) | 2023-07-24 |
JP7397239B2 (ja) | 2023-12-12 |
CA3202226A1 (en) | 2022-05-27 |
MX2023005994A (es) | 2023-08-11 |
US20220177532A1 (en) | 2022-06-09 |
CO2023007172A2 (es) | 2023-06-20 |
JP2023545212A (ja) | 2023-10-26 |
US11939361B2 (en) | 2024-03-26 |
TW202237167A (zh) | 2022-10-01 |
EP4247403A1 (en) | 2023-09-27 |
IL302996A (en) | 2023-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023007172A2 (es) | Composiciones de inhibidores peptídicos del receptor de interleucina-23 | |
AR121070A1 (es) | Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias | |
AR126457A1 (es) | Inhibidores peptídicos bicíclicos del receptor de interleuquina-23 | |
AR119389A1 (es) | Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias | |
ECSP18002929A (es) | Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias | |
CO2024000999A2 (es) | Inhibidores peptídicos lipídicos del receptor de interleucina-23 | |
MX2022008740A (es) | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. | |
BR112022000328A2 (pt) | Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
EP3820883A4 (en) | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN TREATING INFLAMMATORY DISEASES | |
CL2020001020A1 (es) | Derivados de bencimidazol y sus usos. | |
NI202100012A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
MX2022003671A (es) | Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades. | |
ECSP23076906A (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
MX2022010693A (es) | Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades. | |
AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
CR20230177A (es) | Compuestos y composiciones como moduladores de señalización tlr | |
EA202092305A1 (ru) | Соединения в качестве модуляторов сигнализации tlr2 | |
UY37745A (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
CR20210499A (es) | Compuestos y composiciones como moduladores de la señalización de tlr | |
EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
CO2021017960A2 (es) | Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1 | |
CL2018002690A1 (es) | Variantes del anticuerpo humanizado ban2401 que se une específicamente a protofibrillas con una vida media serica aumentada composiciones farmacéuticas y usos en el tratamiento del alzheimer y otras enfermedades neurodegenerativas (divisional de la solicitud n° 53-2017). |